*Quadrivalent influenza vaccine (surface antigen, inactivated, prepared in cell cultures)

Family enjoying time together outdoors, highlighting the importance of Flucelvax Quad vaccination to protect loved ones during flu season

Pharmacy owner Tanya Maloney explains why demand for Flucelvax Quad® has far exceeded her expectations. Watch the video below. 

Flucelvax Quad vaccine box with call-to-action to order 2023 supply for patients, highlighting vaccination availability

References:

  1. CDC. Cell-based flu vaccines. Accessed September 2022. 
  2. Rajaram S et al. Ther Adv Vaccines Immunother. 2020;8:2515135520908121.
  3. Mabrouk T et al. Dev Biol (Basel). 2002;110:125–134. 
  4. WHO. Influenza A(H3N2) lineage cell culture-derived CVVs for development and production of vaccines for use in the 2022 SH influenza season. Accessed September 2022.
  5. FLUCELVAX QUAD® Approved Product Information.

Seqirus (Australia) Pty Ltd Melbourne, Victoria. ABN: 66 120 398 067. ww.seqirus.com.au. Seqirus Medical Information: 1800 642 865. FLUCELVAX® is a registered trademark of Seqirus UK or its affiliates. Seqirus™ is a trademark of Seqirus UK Limited or its affiliates.

Date of preparation: April 2023. ANZ-QIVc-22-0128.

RELATED ARTICLESMORE FROM AUTHOR